Repros in the News

All Releases

View Summary Repros Therapeutics Inc.® Reports First Quarter 2016 Financial Results

May 10, 2016

PDF 23.5 KB Add to Briefcase
View Summary Repros Reports Positive Clinical Data for Vaginal Proellex® in Women With Severe Menstrual Bleeding Due to Uterine Fibroids

Apr 12, 2016

PDF 20.0 KB Add to Briefcase
View Summary Repros Announces Initiation of Formal Approval Process by the European Medicines Agency

Mar 15, 2016

PDF 17.2 KB Add to Briefcase
View Summary Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2015 Financial Results

Mar 14, 2016

PDF 24.8 KB Add to Briefcase
View Summary Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men

Feb 16, 2016

PDF 20.6 KB Add to Briefcase
View Summary Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism

Feb 8, 2016

PDF 16.5 KB Add to Briefcase
View Summary Repros Announces Court of Appeals' Affirmation of Summary Judgment in Favor of the Company

Jan 11, 2016

PDF 13.8 KB Add to Briefcase
View Summary Repros Updates Enclomiphene Program

Jan 4, 2016

PDF 18.7 KB Add to Briefcase
View Summary Repros Updates Proellex® Program

Dec 21, 2015

PDF 20.3 KB Add to Briefcase
View Summary Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene

Dec 1, 2015

PDF 19.9 KB Add to Briefcase
View Summary Repros Therapeutics Completes Randomization of Phase 2b Study of Vaginal Proellex(R) in Women With Symptomatic Uterine Fibroid Bleeding

Nov 12, 2015

PDF 20.4 KB Add to Briefcase
View Summary Repros Therapeutics Inc.(R) Reports Third Quarter 2015 Financial Results

Nov 9, 2015

PDF 25.8 KB Add to Briefcase
View Summary Repros Therapeutics Announces Cancellation of FDA Advisory Committee Meeting to Review Enclomiphene for the Treatment of Secondary Hypogonadism

Oct 29, 2015

PDF 20.0 KB Add to Briefcase
View Summary Repros Therapeutics Inc.(R) Reports Second Quarter 2015 Financial Results

Aug 10, 2015

PDF 25.4 KB Add to Briefcase
View Summary Repros Announces Date of FDA Advisory Committee Review of NDA

Jun 8, 2015

PDF 22.7 KB Add to Briefcase
View Summary Repros Therapeutics Inc.(R) Reports First Quarter 2015 Financial Results

May 7, 2015

PDF 25.4 KB Add to Briefcase
View Summary Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application

Apr 15, 2015

PDF 18.6 KB Add to Briefcase
View Summary Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization Application to the European Medicines Agency as a New Active Substance

Apr 6, 2015

PDF 19.4 KB Add to Briefcase
View Summary Repros Announces Acceptance for Filing of NDA

Apr 1, 2015

PDF 19.4 KB Add to Briefcase
View Summary Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2014 Financial Results

Mar 16, 2015

PDF 29.2 KB Add to Briefcase
Showing 21-40 of 190 Page: 1 2 3 4 5 6 ... 10  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax